Comparing the current results to its competitors, Xencor Inc reported Revenue increase in the 2 quarter 2026 by 17.46 % year on year. The sales growth was above Xencor Inc's competitors' average revenue growth of 6.62 %, achieved in the same quarter.
Xencor Inc's Comment on Competition and Industry Peers
The company operates in a competitive industry characterized by rapid technological advancements, particularly in oncology and autoimmune disease drug development. Its competitors include pharmaceutical and biotechnology companies, academic institutions, and research organizations, many of which possess greater capabilities in scientific research, product development, finance, marketing, sales, and human resources. Several specialized biotechnology firms collaborate with large pharmaceutical companies to support the research, development, and commercialization of competing products. The competitive landscape includes multiple companies developing bispecific antibody platforms with various drug candidates in clinical trials. The company identifies XmAb657 (CD19 x CD3), a bispecific antibody in development, as a competitor molecule studied in Phase 1 hematologic cancer trials, highlighting competition in similar therapeutic areas.
Overall company sales advanced by 17.46 % Xencor Inc outperformed its competitors in this segment and improved market share, to approx. 0.06 %. << More on XNCR Market Share.
*Market share is calculated based on total revenue.
October 24, 2025
Xencor s Bold Advances in Oncology: Initial Results on XmAb819 and Future Prospects in Autoimmune Disease In the intricate landscape of oncology and autoimmune disease treatment, Xencor, Inc. (NASDAQ: XNCR), has emerged as a prominent player dedicated to the development of engineered antibodies potentially transformative for patient care. With a clinical-stage portfolio that focuses on the treatment of cancer and serious chronic diseases, Xencor continues to make remarkable strides. Recently, the company revealed promising initial results from its ongoing Phase 1 dose-escalation study of XmAb819, a revolutionary ENPP3 x CD3 bispecific T-cell engager conceived for the treatment of advanced clear cell renal ce...
October 14, 2025
Innovative Landscape in Oncological Therapies: A Focus on XmAb819 in Clear Cell Renal Cell Carcinoma and Xencor s Competitive Position Renal cell carcinoma (RCC) has seen a paradigm shift in treatment strategies over the last decade, particularly with the advent of immuno-oncology. Among various treatment modalities, bispecific antibodies are emerging as a promising class of therapeutic agents designed to redirect T-cells to recognize and eliminate cancer cells more effectively. Xencor, Inc. stands at the forefront of this innovation, with its lead candidate, XmAb819, currently under investigation in a Phase 1 dose-escalation study for clear cell renal cell carcinoma (ccRCC). This article synthesizes insigh...
September 9, 2024
Xencor Inc. has made significant strides in the development of its XmAb drug candidates targeting autoimmune diseases, alongside notable clinical progress in early-stage oncology programs. However, the company s financial performance metrics particularly revenue per employee have raised questions about its operational efficiency within the competitive healthcare sector. Xencor Inc. a biopharmaceutical company focused on developing innovative antibodies for cancer and autoimmune diseases, is currently navigating through a period of clinical advancements and financial challenges. The recent announcement of near-term clinical plans for its XmAb drug candidates illustrates the company s commitment to combatt...
September 6, 2024
Xencor, Inc. (NASDAQ: XNCR), a notable clinical-stage biopharmaceutical company based in Pasadena, California, is making significant strides in the development of engineered antibodies. This innovative company is focused on creating advanced treatment options for cancer and other serious diseases. On September 9, 2024, Xencor will host a research and development (RandD) webcast and conference call to reveal cutting-edge XmAb programs for autoimmune diseases and to provide updates on the progress of dose-escalation studies in their current pipeline. Background on Xencor, Inc. Xencor has pioneered technologies that enhance the therapeutic properties of monoclonal antibodies. Their XmAb® antibody engineering p...
Dianthus Therapeutics Inc is a biotechnology company that focuses on developing novel genetic medicines for patients suffering from rare genetic diseases. Their business model revolves around leveraging cutting-edge gene therapy technologies to design and deliver innovative treatments. By partnering with academic institutions and utilizing a proprietary gene therapy platform, they aim to address unmet medical needs and provide potential new therapies for patients with genetic disorders.
Acelyrin Inc is a technology company that focuses on providing cutting-edge solutions in the healthcare industry. Their business model is centered around developing innovative software and hardware products that improve patient outcomes, enhance operational efficiency, and drive cost savings for healthcare organizations. By offering a range of advanced tools and services, Acelyrin Inc aims to revolutionize the healthcare sector and contribute to the overall advancement of digital health.
Azitra Inc is a company that operates on a business model focused on developing and commercializing microbiome-based therapeutics for various skin conditions. It aims to use the potential of the human skin microbiome to develop innovative and effective treatments.
Sources:
Xencor Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Xencor Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
